Core Viewpoint - The stock of Aojing Medical (688613) has shown a significant increase, closing at 25.41 yuan on February 10, 2026, with a rise of 5.13% and notable trading activity [1] Group 1: Stock Performance - On February 10, 2026, Aojing Medical's stock price increased by 5.13%, with a trading volume of 115,800 shares and a total transaction value of 289 million yuan [1] - The stock's turnover rate was 8.45%, indicating active trading [1] Group 2: Capital Flow - On February 10, 2026, the net inflow of main funds was 16.23 million yuan, accounting for 5.62% of the total transaction value, while retail investors experienced a net outflow of 25.61 million yuan, representing 8.87% of the total [1][2] - Over the past five days, the stock has seen fluctuating capital flows, with the highest net inflow of main funds recorded on February 9, 2026, at 2.45 million yuan [2] Group 3: Financing and Margin Trading - On February 10, 2026, the financing buy-in was 47.74 million yuan, with a net financing purchase of 9.29 million yuan, marking a cumulative net purchase of 13.24 million yuan over three consecutive days [2][3] - The margin trading balance stood at 235 million yuan, with a short selling volume of 4,771 shares and a remaining short selling balance of 38,300 yuan [3] Group 4: Company Financials and Industry Comparison - Aojing Medical reported a total market value of 3.481 billion yuan, with a net profit of 13.94 million yuan, reflecting a year-on-year increase of 185.19% [5] - The company's gross profit margin is 68.9%, significantly higher than the industry average of 50.61%, ranking 25th in the industry [5] - The company's return on equity (ROE) is 0.98%, which is above the industry average of 0.52%, ranking 89th in the industry [5]

Core Viewpoint - The stock of Aojing Medical (688613) has shown a significant increase, closing at 24.17 yuan on February 9, 2026, with an 8.58% rise, indicating positive market sentiment towards the company [1]. Group 1: Stock Performance - On February 9, 2026, Aojing Medical's trading volume was 79,600 hands, with a total transaction amount of 189 million yuan [1]. - The stock's turnover rate was 5.81%, reflecting active trading [1]. Group 2: Capital Flow - On February 9, 2026, the net inflow of main funds was 2.45 million yuan, accounting for 1.29% of the total transaction amount, while retail investors saw a net inflow of 2.69 million yuan, representing 1.42% of the total [1]. - Over the past five days, the financing data showed a net purchase of 1.41 million yuan on that day, with a cumulative net purchase of 5.72 million yuan over three days [2]. Group 3: Financial Performance - For the first three quarters of 2025, Aojing Medical reported a main revenue of 156 million yuan, a year-on-year increase of 5.22%, and a net profit attributable to shareholders of 13.94 million yuan, up 185.19% [3]. - In the third quarter of 2025, the company achieved a single-quarter main revenue of 56.02 million yuan, a 16.54% increase year-on-year, and a net profit of 5.97 million yuan, reflecting a 237.64% rise [3]. - The company's gross profit margin stood at 68.9%, indicating strong profitability in its operations [3].

Group 1 - The stock of Aojing Medical (688613) closed at 22.56 yuan on January 8, 2026, with an increase of 4.44% and a turnover rate of 5.78% [1] - The total trading volume was 79,200 hands, with a transaction amount of 176 million yuan [1] - On January 8, the net inflow of main funds was 26.66 million yuan, accounting for 15.13% of the total transaction amount, while retail investors had a net outflow of 20.43 million yuan, accounting for 11.6% [1] Group 2 - In the financing and securities lending data, the financing buy amounted to 30.56 million yuan, with a net financing increase of 11.78 million yuan [2] - The total financing and securities lending balance was 198 million yuan [2] - Aojing Medical's main business includes the research, production, and sales of high-end biomedical materials and related medical devices [3] Group 3 - For the first three quarters of 2025, Aojing Medical reported a main revenue of 156 million yuan, a year-on-year increase of 5.22%, and a net profit attributable to shareholders of 13.94 million yuan, up 185.19% [3] - In Q3 2025, the company achieved a single-quarter main revenue of 56.02 million yuan, a year-on-year increase of 16.54%, and a net profit of 5.97 million yuan, up 237.64% [3] - The company's debt ratio was 6.22%, with a gross profit margin of 68.9% [3]

Core Viewpoint - The stock of Aojing Medical (688613) has shown a slight increase of 1.93% on December 15, 2025, closing at 20.02 yuan, with notable fluctuations in capital flow and financing activities [1][2]. Group 1: Stock Performance and Capital Flow - On December 15, 2025, Aojing Medical's stock closed at 20.02 yuan, with a trading volume of 40,400 hands and a total transaction amount of 80.583 million yuan [1]. - The capital flow data indicates a net inflow of 1.763 million yuan from main funds, accounting for 2.19% of the total transaction amount, while retail investors experienced a net outflow of 4.106 million yuan, representing 5.09% of the total [1][2]. - Over the past five days, the stock has experienced fluctuations in capital flow, with the highest net inflow from main funds recorded at 20.0116 million yuan on December 10, 2025 [2]. Group 2: Financing and Margin Trading - On December 15, 2025, the financing buy-in amounted to 12.8433 million yuan, with a net financing buy-in of 6.7929 million yuan, while the total financing balance reached 163 million yuan [3]. - The financing data over the past five days shows a trend of fluctuating net financing buy-ins, with a peak of 9.6018 million yuan on December 9, 2025 [3]. Group 3: Company Financial Performance - Aojing Medical reported a main revenue of 156 million yuan for the first three quarters of 2025, reflecting a year-on-year increase of 5.22%, with a net profit of 13.9406 million yuan, up 185.19% [5]. - The company's gross profit margin stands at 68.9%, significantly higher than the industry average of 51.02%, indicating strong operational efficiency [5]. - The company's total market capitalization is 2.743 billion yuan, with a net asset value of 1.449 billion yuan, positioning it below the industry average in several key financial metrics [5].

Core Viewpoint - The stock of Aojing Medical (688613) has experienced a decline of 2.52% as of September 17, 2025, closing at 27.8 yuan, with significant net outflows from retail investors and a mixed performance in institutional and speculative trading [1][2]. Group 1: Stock Performance and Trading Data - On September 17, 2025, Aojing Medical's stock closed at 27.8 yuan, down 2.52%, with a turnover rate of 7.11% and a trading volume of 97,400 hands, resulting in a transaction amount of 271 million yuan [1]. - The net inflow of institutional funds was 26.25 million yuan, accounting for 9.68% of the total transaction amount, while speculative funds saw a net outflow of 9.54 million yuan (3.52%), and retail investors had a net outflow of 16.71 million yuan (6.16%) [1][2]. Group 2: Financing and Margin Trading Data - On September 17, 2025, the financing buy-in was 21.97 million yuan, while the financing repayment was 32.39 million yuan, resulting in a net repayment of 10.42 million yuan [2][3]. - The total margin trading balance stood at 142 million yuan, with no shares sold or repaid in the short selling segment [2][3]. Group 3: Company Financials and Industry Comparison - Aojing Medical reported a main business revenue of 100 million yuan for the first half of 2025, a year-on-year decrease of 0.2%, and a net profit attributable to shareholders of 7.98 million yuan, down 13.52% year-on-year [5]. - The company’s gross profit margin was 63.12%, significantly higher than the industry average of 51.85%, while its net profit margin was 5.53%, lower than the industry average of 10.39% [5]. - Aojing Medical's total market capitalization is 3.809 billion yuan, with a net asset value of 1.444 billion yuan, and it ranks 94th in the industry based on market capitalization [5].

Core Viewpoint - The stock of Aojing Medical (688613) has experienced a decline of 4.4% as of September 10, 2025, closing at 25.42 yuan, with significant net outflows from major funds and a mixed performance from retail investors [1][2]. Financial Performance - Aojing Medical reported a main revenue of 100 million yuan for the first half of 2025, a year-on-year decrease of 0.2% [5]. - The net profit attributable to shareholders was 7.9753 million yuan, down 13.52% year-on-year [5]. - The second quarter of 2025 showed a single-quarter main revenue of 57.5772 million yuan, an increase of 8.88% year-on-year, and a net profit of 6.9338 million yuan, up 203.59% year-on-year [5]. Market Activity - On September 10, 2025, the stock had a trading volume of 134,700 hands and a transaction amount of 341 million yuan [1]. - The net outflow of major funds was 45.0152 million yuan, accounting for 13.21% of the total transaction amount, while retail investors saw a net inflow of 33.3271 million yuan, representing 9.78% of the total [1][2]. Financing and Margin Trading - As of September 10, 2025, the financing balance was 178 million yuan, with a net financing purchase of 2.518 million yuan [3]. - There were no short selling activities reported on that day, indicating a stable margin trading environment [3]. Industry Comparison - Aojing Medical's total market capitalization is 3.483 billion yuan, significantly lower than the industry average of 12.107 billion yuan, ranking 97 out of 123 in the medical device sector [5]. - The company's gross margin stands at 63.12%, which is above the industry average of 51.85%, ranking 42 out of 123 [5].

Group 1 - The stock of Aojing Medical (688613) closed at 21.5 yuan on September 5, 2025, with an increase of 9.19% and a turnover rate of 6.38% [1] - The net inflow of main funds on September 5 was 2.77 million yuan, accounting for 1.52% of the total turnover, while retail investors had a net inflow of 7.08 million yuan, accounting for 3.90% [1] - Over the past five days, the stock has experienced fluctuations in fund flows, with notable changes in retail and main fund activities [1][2] Group 2 - Aojing Medical's financing data shows a net purchase of 8.74 million yuan on September 5, with a total financing balance of 158 million yuan [2] - The company's main business revenue for the first half of 2025 was 100 million yuan, a year-on-year decrease of 0.2%, while the net profit attributable to shareholders was 7.98 million yuan, down 13.52% year-on-year [4] - The company reported a gross profit margin of 63.12% and a net profit margin of 5.53%, indicating a relatively strong profitability compared to industry averages [4] Group 3 - Aojing Medical's total market value is 2.946 billion yuan, significantly lower than the industry average of 11.933 billion yuan [4] - The company ranks 90th in net profit within the medical device industry, with a net profit of 7.98 million yuan compared to the industry average of 149 million yuan [4] - The company's price-to-earnings ratio (184.67) is considerably higher than the industry average (65.4), indicating potential overvaluation [4]

Core Viewpoint - The stock of Aojing Medical (688613) has shown a recent increase in price, with a closing price of 20.26 yuan on August 8, 2025, reflecting a rise of 2.22% [1] Financial Performance - Aojing Medical reported a main revenue of 42.46 million yuan for Q1 2025, representing a year-on-year decline of 10.35% [5] - The net profit attributable to shareholders was 104.15 thousand yuan, down 84.99% year-on-year [5] - The company’s gross profit margin stood at 60.71%, which is higher than the industry average of 51.35% [5] Market Activity - On August 8, 2025, the net inflow of main funds was 16.87 million yuan, accounting for 12.36% of the total transaction amount [1] - Retail investors experienced a net outflow of 10.45 million yuan, representing 7.65% of the total transaction amount [1] - The stock's turnover rate was 4.93%, with a total transaction amount of 136 million yuan [1] Financing and Margin Trading - On August 8, 2025, the financing balance was 138 million yuan, with a net purchase of 6.56 million yuan [3] - The company had no short selling activity, with a margin balance of 138 million yuan [3] Industry Comparison - Aojing Medical's total market capitalization is 2.776 billion yuan, significantly lower than the industry average of 11.731 billion yuan [5] - The company has a price-to-earnings ratio of 666.29, which is substantially higher than the industry average of 65.84 [5] - The return on equity (ROE) for Aojing Medical is 0.07%, compared to the industry average of 1.15% [5]